Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13292851 | 0.96 | KMT2A (0.50) | ALDH1A1LMNAMAPTKMT2AMEN1 | |
| SCHEMBL6605777 | 0.94 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPTKMT2AMEN1 | |
| Morpholine SCHEMBL27719 | 0.88 | SIRT6 (0.47) | ALDH1A1LMNAMAPTKMT2AMEN1 | |
| SCHEMBL3136982 | 0.86 | CUL4A (0.51) | ALDH1A1LMNAMAPTSIRT6POLB | |
| SCHEMBL2886399 | 0.82 | MAPT (0.49) | ALDH1A1LMNAMAPTMAPK1HRH3 | |
| SCHEMBL12006068 | 0.82 | MAPT (0.49) | ALDH1A1LMNAMAPTMAPK1HRH3 | |
| SCHEMBL28185991 | 0.81 | MAPT (0.47) | ALDH1A1LMNAMAPTKMT2AMEN1 | |
| SCHEMBL6095682 | 0.81 | MAPT (0.47) | ALDH1A1LMNAMAPTKMT2AMEN1 | |
| SCHEMBL1092846 | 0.81 | MAPT (0.47) | ALDH1A1MAPTMAPK1SIRT6POLB | |
| SCHEMBL5653005 | 0.81 | MAPT (0.47) | ALDH1A1MAPTMAPK1SIRT6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102827082-B | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO CO LTD | 2015-01-07 | — | — | CN | disclosed |
| CN-102341385-B | Piperazine compound capable of inhibiting prostaglandin d synthase | TAIHO PHARMACEUTICAL CO LTD | 2014-01-15 | — | — | CN | disclosed |
| CN-102341385-A | Piperazine compound capable of inhibiting prostaglandin d synthase | TAIHO PHARMACEUTICAL CO LTD | 2012-02-01 | — | — | CN | disclosed |
| US-20040198731-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040198732-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040198733-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040192693-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-30 | — | — | US | disclosed |
| US-20030212070-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212070-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | ALDH1A1 404/4885LMNA 1397/4885MAPT 3514/4885 |
| US-20040192693-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | ALDH1A1 404/4885LMNA 1397/4885MAPT 3514/4885 |
| US-20040198731-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | ALDH1A1 404/4885LMNA 1397/4885MAPT 3514/4885 |
| US-20040198733-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | ALDH1A1 404/4885LMNA 1397/4885MAPT 3514/4885 |
| US-20040198732-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | ALDH1A1 404/4885LMNA 1397/4885MAPT 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.